AHeaD – Assessing Health in a Digitalizing Real-World Setting Pharmacoepi & beyond

Pr. Antoine Pariente, PharmD, PhD, AHEAD Director
Dr. Gayo DIALLO, PhD, AHEAD Deputy Director


We are interested in better understanding healthcare real-world setting and better assessing medicines in this observational environment. In particular, we aim to investigate trajectories of care and their determinants, with a specific interest into emergency care use from one side, and trajectories of care for patients with chronic diseases relating to cardiovascular health or mental health from the other.


Research areas

In the past five years, we belonged to three different teams (“Pharmacoepidemiology – Pharmacoepi”; “Injuries – IETO”; “Informatics in Health – ERIAS”). The collaborations we developed ultimately concentrated most of our teams research efforts, typically around the secondary use of electronic databases for the study of health and medicines in a real-world setting,

Anticipating the research challenges that will emerge from the multiplication, diversification, and complexification of digital health data, we decided to join forces into the AHeaD team project.
This will combine our originating teams expertise in electronic health records databases (HERs), hospital datawarehouses, ontologies, data visualization, knowledge representation, and machine learning and natural language processing for health research, thus constituting a tremendous research opportunity.

Indeed, if the questions and needs for health assessment in real-world settings will remain, how to answer these questions will likely change dramatically. In the coming years, the use of electronic health databases, that developed tremendously over the past 30 years, will need to be complemented using information from other sources that will help strengthen and substantiate the real-world evidence provided. Building bridges between applied health research, already widely using EHRs, and informatics consequently appears as a requirement when envisioning the future development of health-assessment in real-world settings.

The research will divide into three axes corresponding to different objectives and methods:

1. Data & Signals: Structuring and bridging data for hypothesis-generating in real-world assessment
Safety signal or repurposing hypotheses are mostly presented or generated from the results obtain from one datasource/type of information analysis. We Intent to go further by developing approaches that will combine various type/sources of Information for hypothesis-generating research from real-world data.

2. Use & Effectiveness: Stay focus, remain global
Medicines & health determinants assessment is better performed when closely focusing on one medicines or care. The detriment is to lose sight of the overall care environment (therapeutic alternatives; healthcare trajectories). We intent to develop research that will deeper contextualize and characterize the overall healthcare use surrounding targeted research regarding the use or effectiveness of a given medicines or care.

3. Policies & Impact: Assessing the public health impact of regulatory actions
Ultimately, the hypotheses generated/confirmed within the two first research axes can result in official recommendations or regulatory actions aiming to optimize healthcare strategies. Our research will here assess to which extent these are successfully adopted and benefic to health, thereby completing our research path from hypothesis-generation to translation to society.

2021 Key Publications

Altman MC, Rinchai D, Baldwin N, Toufiq M, Whalen E, Garand M, Syed Ahamed Kabeer B, Alfaki M, Presnell SR, Khaenam P, Ayllon-Benitez A, Mougin F, Thebault P, Chiche L, Jourde-Chiche N, Phillips JT, Klintmalm G, O’Garra A, Berry M, Bloom C, Wilkinson RJ, Graham CM, Lipman M, Lertmemongkolchai G, Bedognetti D, Thiebaut R, Kheradmand F, Mejias A, Ramilo O, Palucka K, Pascual V, Banchereau J, Chaussabel D. Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nat Commun. 2021 Jul 19;12(1):4385. https://doi.org/10.1038/s41467-021-24584-w
Gil-Jardiné C, Chenais G, Pradeau C, Tentillier E, Revel P, Combes X, Galinski M, Tellier E, Lagarde E. Trends in reasons for emergency calls during the COVID-19 crisis in the department of Gironde, France using artificial neural network for natural language classification. Scand J Trauma Resusc Emerg Med. 2021 Mar 31;29(1):55. https://doi.org/10.1186/s13049-021-00862-w

Klann JG, Weber GM, Estiri H, Moal B, Avillach P, Hong C, Castro V, Maulhardt T, Tan ALM, Geva A, Beaulieu-Jones BK, Malovini A, South AM, Visweswaran S, Omenn GS, Ngiam KY, Mandl KD, Boeker M, Olson KL, Mowery DL, Morris M, Follett RW, Hanauer DA, Bellazzi R, Moore JH, Loh NW, Bell DS, Wagholikar KB, Chiovato L, Tibollo V, Rieg S, Li A, Jouhet V, Schriver E, Samayamuthu MJ, Xia Z, Hutch M, Luo Y, Consortium for Clinical Characterization of C-bEHR, Kohane IS, Brat GA, Murphy SN. Validation of an Internationally Derived Patient Severity Phenotype to Support COVID-19 Analytics from Electronic Health Record Data. J Am Med Inform Assoc. 2021 Feb 10;28(7):1411-20. https://doi.org/10.1093/jamia/ocab018

Letinier L, Jouganous J, Benkebil M, Bel-Letoile A, Goehrs C, Singier A, Rouby F, Lacroix C, Miremont G, Micallef J, Salvo F, Pariente A. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions. Clin Pharmacol Ther. 2021 Apr 18;110(2):392-400. https://doi.org/10.1002/cpt.2266

Osman I, Ben Yahia S, Diallo G. Ontology Integration: Approaches and Challenging Issues. Inform Fusion. 2021 Jul;71:38-63. https://doi.org/10.1016/j.inffus.2021.01.007

Ramiz L, Contrand B, Rojas Castro MY, Dupuy M, Lu L, Sztal-Kutas C, Lagarde E. A longitudinal study of mental health before and during COVID-19 lockdown in the French population. Global Health. 2021 Mar 22;17(1):29. https://doi.org/10.1186/s12992-021-00682-8

Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, Drici M-D, Valnet-Rabier M-B, Micallef J, Salvo F, Treluyer J-M, Liu PP. Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. 2022 Mar;111(3):605-13. https://doi.org/10.1002/cpt.2499
Gil-Jardine C, Chenais G, Pradeau C, Tentillier E, Revel P, Combes X, Galinski M, Tellier E, Lagarde E. Surveillance of COVID-19 using a keyword search for symptoms in reports from emergency medical communication centers in Gironde, France: a 15 year retrospective cross-sectional study. Intern Emerg Med. 2022 Mar;17(2):603-8. https://doi.org/10.1007/s11739-021-02818-5

Linard M, Bezin J, Hucteau E, Joly P, Garrigue I, Dartigues J-F, Pariente A, Helmer C. Antiherpetic drugs: a potential way to prevent Alzheimer’s disease? Alzheimers Res Ther. 2022 Jan 7;14(1):3. https://doi.org/10.1186/s13195-021-00950-0

Tournier M, Pambrun E, Maumus-Robert S, Pariente A, Verdoux H. The risk of dementia in patients using psychotropic drugs: Antidepressants, mood stabilizers or antipsychotics. Acta Psychiatr Scand. 2022 Jan;145(1):56-66. https://doi.org/10.1111/acps.13380


Centre de recherche INSERM U1219
Université de Bordeaux – ISPED case 11
146 rue Léo-Saignat
33076 BORDEAUX cedex
Tél : +33 (0)5 57 57 95 12


  • Director:
    Directeur – Equipe Pharmaco-épidémiologie

    Médecin spécialiste en Santé Publique, Antoine Pariente a complété sa formation médicale en effectuant un cursus de spécialisation complémentaire en pharmacologie et évaluation des thérapeutiques. Parallèlement a ses études de médecine, il a suivi une formation à la recherche en santé publique  et obtenu un Master en Epidémiologie et biostatistique (Université de Bordeaux) avant de compléter une Thèse d’Université en Pharmaco-épidémiologie (Université de Bordeaux – Université de Montréal). Ses axes de recherche principaux sont la pharmaco-épidémiologie des personnes âgées et des maladies chroniques, et la détection de signaux en pharmacovigilance.

    Graduated from the medical faculty of Bordeaux as an MD with specialisation in Public Health, A. Pariente completed his medical training with a complementary specialisation in Pharmacology. Concomitantly to his medical studies, he obtained a Master Degree in Public Health at the Bordeaux Institute of Public Health and further completed his research training with a PhD in pharmacoepidemiology (University of Bordeaux-University of Montreal). His main research axes in pharmacoepidemiology focus on the elder and chronic diseases ; they focus in methods and biases for safety signal detection from spontaneous reporting in pharmacovigilance.


  • Co-Director:
    HDR- Maître de Conférences en Informatique – Directeur Team ERIAS
    BPH Centre Inserm 1219 – Team ERIAS


    2019: Habilitation à Diriger des Recherches

    2009- : Maître de Conférences en Informatique

    2008-2009: Chercheur Post-doc, LISI -ENSMA Futuruscope, Poitiers, Fr

    2007-2008: Research Assistant, City University of London, UK,

    12/2006: Doctorat en Informatique, Université de Grenoble 1 Joseph Fourier

    2004-2006: ATER en Informatique, Université de Grenoble 2 Pièrre Mendes France

    2001-2004: Allocataire (Univ. Grenoble 1)-Moniteur de Recherche (Univ. Grenoble 2)

    Fev- Mai 2001: Vacataire d’Enseignement, IUT 2 de Grenoble

  • Contact: Marie-Annick Gauvrit



Département de recherche santé publique Université de Bordeaux logo_ISPED logo_INRIA logo_HONcode